Follow us on Bluesky
  1. Bluesky Feeds /
  2. Mokurai /
  3. Diabetes Researth
Diabetes Researth

Diabetes Researth

by Mokurai Mokurai

Best sources of information on diabetes research on Bluesky

Feed on Bluesky

Feeds Stats

  • 💙 Liked by 1 user
  • 📅 Updated 5 months ago
  • ⚙️ Provider skyfeed.me

Diabetes Researth Likes over time

Like count prediction
The feed Diabetes Researth gains approximately 2 likes per month.

Feed Preview for Diabetes Researth

European Association for the Study of Diabetes
@easdnews.bsky.social
about 9 hours ago
📢 #SpeakerHighlight! Everything to know about #glucagon in #diabetes - in one session - "Glucagon: No longer the bad guy in diabetes?". Join Prof. Müller (@www.helmholtz-munich.de) at #EASD2025: 🧬 "Glucagon regulation of energy metabolism" 📅 Thurs, 18 September | 🕒 08:30 - 09:15 CEST 📍 Milan Hall
Promotional graphic for a speaker highlight at EASD 2025 in Vienna. The session is titled "Glucagon: No longer the bad guy in diabetes?" with the topic "Glucagon regulation of energy metabolism." The session is scheduled for 18 September 2025, from 08:30 to 09:15 CEST. The speaker is Timo Müller, whose photo appears in a circular frame. The EASD 2025 Vienna logo is at the bottom left, and the words "Speaker Highlight" are written at the bottom. The background is primarily red, white, and blue.
0
0
3
European Association for the Study of Diabetes
@easdnews.bsky.social
1 day ago
📢 Don’t miss the next #EarlyCareer Academy #webinar with Prof. Peter Rossing from #Steno Diabetes Center, Copenhagen. Explore how advances in #kidney protection in #T2D might help shape care in #T1D. 🗓️ 21 Aug 2025 |🕛 16:30 CEST 🔗 Register: us06web.zoom.us/meeting/r…. #CKD #DKD #DiabetesCare
0
0
1
The Lancet Diabetes & Endocrinology
@thelancetendo.bsky.social
1 day ago
Efficacy and safety of automated #insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial thelancet.com/journals/lan... #AID #T1D #MedSky #EndoSky
0
0
2
European Association for the Study of Diabetes
@easdnews.bsky.social
2 days ago
📟 A phase II study tested #GLP1 RA #semaglutide at doses of up to 16 mg - 8x the currently approved maximum. First-author Vanita Aroda explains how it improves body weight and #glycaemic control, but at the cost of reduced tolerability. Read more 👉 easd-elearning.eu/news/451/Hig... #Diabetes #T2D
Infographic of a phase 2, double-blind, randomised trial on high-dose semaglutide (up to 16 mg) in 245 people with type 2 diabetes and BMI ≥27 kg/m² on metformin. Participants received once-weekly semaglutide or placebo for 40 weeks. Study arms: Placebo (n=60), 2 mg (n=61), 8 mg (n=62), 16 mg (n=62). HbA1c change (%): -1.0 (placebo), -1.8 (2 mg), -1.8 (8 mg), -2.1 (16 mg); 16 mg vs 2 mg: -0.3 (p=0.245). Weight change (kg): -2.6 (placebo), -8.3 (2 mg), -9.3 (8 mg), -11.7 (16 mg); 16 mg vs 2 mg: -3.4 (p=0.011). Gastrointestinal AEs: 34% (placebo), 47% (2 mg), 68% (8 mg), 71% (16 mg). Discontinuation: 2% (placebo), 7% (2 mg), 23% (8 mg), 18% (16 mg). Severe hypoglycaemia: 0% across all groups.
0
1
1